Cargando…

Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion

Detalles Bibliográficos
Autores principales:	Olson, Michael L., Mause, Erica R. Vander, Radhakrishnan, Sabarinath V., Brody, Joshua D., Rapoport, Aaron P., Welm, Alana L., Atanackovic, Djordje, Luetkens, Tim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252916/ https://www.ncbi.nlm.nih.gov/pubmed/35490197 http://dx.doi.org/10.1038/s41375-022-01585-2

Ejemplares similares

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2020)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
por: Ramezani, Faezeh, et al.
Publicado: (2023)

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
por: Schoutrop, Esther, et al.
Publicado: (2022)

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation
por: Templin, Julia, et al.
Publicado: (2017)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
por: Camviel, Nicolas, et al.
Publicado: (2022)

Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy
por: Dahiya, Saurabh, et al.
Publicado: (2022)

The expansion of targetable biomarkers for CAR T cell therapy
por: Townsend, Michelle H., et al.
Publicado: (2018)

Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model
por: Singh, Aman P., et al.
Publicado: (2019)

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy
por: Dahiya, Saurabh, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)
por: Kline, Kathryn, et al.
Publicado: (2023)

Anti-SARS-CoV-2 Immune Responses in Patients Receiving an Allogeneic Stem Cell or Organ Transplant
por: Atanackovic, Djordje, et al.
Publicado: (2021)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Shaping of T Cell Functions by Trogocytosis
por: Nakayama, Masafumi, et al.
Publicado: (2021)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

CAR models: next-generation CAR modifications for enhanced T-cell function
por: Abate-Daga, Daniel, et al.
Publicado: (2016)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion
por: Rejeski, Kai, et al.
Publicado: (2023)

The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
por: Mao, Rui, et al.
Publicado: (2022)

How I treat cytopenias after CAR T-cell therapy
por: Jain, Tania, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
por: Nai, Yaru, et al.
Publicado: (2021)

T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
por: Klaver, Yarne, et al.
Publicado: (2016)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

CAR-T Cell Therapy
por: Ahmad, Aamir
Publicado: (2020)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Trogocytosis in Unicellular Eukaryotes
por: Nakada-Tsukui, Kumiko, et al.
Publicado: (2021)

Counteracting CAR T cell dysfunction
por: Poorebrahim, Mansour, et al.
Publicado: (2021)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells
por: Thomas, Simone, et al.
Publicado: (2023)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

X-ray-irradiated K562 feeder cells for expansion of functional CAR-T cells
por: Bui, Khac Cuong, et al.
Publicado: (2022)

Impact of serum-free media on the expansion and functionality of CD19.CAR T-cells
por: Eberhardt, Franziska, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6a5e7cpcbakaolsim6li6q3314